Centre de Recerca en Salut Internacional de Barcelona, Hospital Clinic, Universitat de Barcelona, C/Rosselló 149-153, Barcelona, Spain.
Int J Antimicrob Agents. 2012 Sep;40(3):196-203. doi: 10.1016/j.ijantimicag.2012.02.011. Epub 2012 Jul 23.
Quinolones were introduced into clinical practice in the late 1960s. Although quinolone resistance was described early, no transferable mechanism of quinolone resistance (TMQR) was confirmed until 1998. To date, five different TMQRs have been described in the literature, including target protection (Qnr), quinolone modification (AAC(6')-Ib-cr), plasmid-encoded efflux systems (e.g. QepA or OqxAB, amongst others), effect on bacterial growth rates and natural transformation. Although TMQRs usually only result in a slight increase in the minimum inhibitory concentrations of quinolones, they possess an additive effect and may facilitate the acquisition of full quinolone resistance. The emergence of new related genes may continue in the next years.
喹诺酮类药物于 20 世纪 60 年代末引入临床实践。尽管早在早期就描述了喹诺酮耐药性,但直到 1998 年才证实了可转移的喹诺酮耐药机制 (TMQR)。迄今为止,文献中已经描述了五种不同的 TMQRs,包括靶位保护 (Qnr)、喹诺酮修饰 (AAC(6')-Ib-cr)、质粒编码的外排系统(如 QepA 或 OqxAB 等)、对细菌生长速度的影响和自然转化。尽管 TMQRs 通常仅导致喹诺酮的最小抑菌浓度略有增加,但它们具有相加作用,并可能促进完全喹诺酮耐药的获得。未来几年可能会继续出现新的相关基因。